Featured Insights
-
Insights From Pharma 2025: Leadership In Pharma – Empowering Change Through Innovative Thinking
6/12/2025
What does it take to lead in today's evolving pharmaceutical landscape? Insights from Pharma 2025 reveal that empowering teams through trust, experimentation, and a shared purpose is key.
-
Inclusion Of Health-Related Quality Of Life (HRQoL) And Other Patient-Reported Outcomes (PROs) In FDA Labels
6/12/2025
With a growing emphasis on patient-centric drug development, new research examines how frequently patient-reported outcomes are actually making it onto United States Food and Drug Administration labels.
-
Value Of Multi-Indication Immunotherapies For The Treatment Of Autoimmune Diseases In The United States
6/12/2025
As multi-indication therapies become more common, new research questions their value. A study for ISPOR 2025 reveals a potential misalignment between the price and value of these versatile treatments.
-
Impact Of JCA And Project Orbis On The European Revenue Potential Of An Oncology Product
6/12/2025
Contrary to concerns about price erosion, new analysis suggests Joint Clinical Assessment and Project Orbis will likely increase European oncology product revenue by enabling faster market uptake.
-
Creating A Compliant And Scalable CGT Logistics Launch Plan
6/12/2025
As cell and gene therapies advance to commercialization, biopharma companies face immense logistical hurdles. A customized, end-to-end strategy is crucial for ensuring product integrity and market success.
-
Preparing For Change: Rare Disease Launches In The Era Of EU Health Technology Assessment (HTA)
5/9/2025
Experts at Pharma 2025 discussed the impending EU Health Technology Assessment and its implications for rare disease product launches, highlighting key challenges and necessary organizational adaptations for the pharmaceutical industry.
-
Harnessing AI: Revolutionizing Drug Discovery And Early Disease Detection
5/9/2025
The power of data and algorithms is unlocking new frontiers in healthcare. Pharma 2025 discussions focused on AI's role in revolutionizing drug discovery and early detection.
-
Navigating The Evolution Of EU Health Technology Assessment (HTA) Regulation
5/9/2025
The future of pharmaceutical access in Europe is being shaped by the new EU HTA regulation. Insights from Pharma 2025, featuring Herbert Altmann and Alexander Natz, shed light on this pivotal shift.
-
Exploring Payer Coverage Of Anti-Obesity Medications
4/14/2025
Understanding payer strategies for anti-obesity drugs is crucial. A recent study investigated commercial formulary trends, confirming cost as a major barrier despite positive patient outcomes.
-
Exploring Value-Based Contracting In Rare Diseases
4/14/2025
How are payers using value-based contracts for costly rare disease therapies? Exploratory research sheds light on negotiation frequency, preferred contract types, and internal data management trends.